Literature DB >> 11274321

Modafinil for excessive daytime sleepiness in myotonic dystrophy.

M S Damian1, A Gerlach , F Schmidt, E Lehmann , H Reichmann.   

Abstract

The authors conducted an open-label trial of modafinil for excessive daytime sleepiness in myotonic dystrophy. Eleven patients were evaluated: two were not treated because of obstructive sleep apnea, and nine received 200 to 400 mg modafinil/day for an average of 16.4 weeks. There were no major side effects. Average sleep latency as measured by the Multiple Sleep Latency Test increased from 7.3 to 22.7 minutes ( p = 0.00013), and average Epworth Sleepiness Scale score decreased from 13.25 to 7.75 (p = 0.01028). Modafinil shows evidence of effectiveness for excessive daytime somnolence in myotonic dystrophy and should be investigated further.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274321     DOI: 10.1212/wnl.56.6.794

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy.

Authors:  Michael Thorpy
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

Review 2.  Diagnostics and therapy of muscle channelopathies--Guidelines of the Ulm Muscle Centre.

Authors:  F Lehmann-Horn; K Jurkat-Rott; R Rüdel
Journal:  Acta Myol       Date:  2008-12

3.  Sleep-disordered Breathing in Neuromuscular Disease.

Authors:  Christian Guilleminault; Ravinder P. Shergill
Journal:  Curr Treat Options Neurol       Date:  2002-03       Impact factor: 3.598

Review 4.  Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management.

Authors:  Svenja Happe
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease.

Authors:  J M de Vries; M L C Hagemans; J B J Bussmann; A T van der Ploeg; P A van Doorn
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

Review 6.  Management of fatigue in patients with multiple sclerosis.

Authors:  Udo A Zifko
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  [Therapy of day time fatigue in patients with multiple sclerosis].

Authors:  Udo A Zifko
Journal:  Wien Med Wochenschr       Date:  2003

Review 8.  Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy.

Authors:  D Annane; D H Moore; P R J Barnes; R G Miller
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

9.  Does modafinil enhance activity of patients with myotonic dystrophy?: a double-blind placebo-controlled crossover study.

Authors:  A R Wintzen; G J Lammers; J G van Dijk
Journal:  J Neurol       Date:  2007-02-06       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.